Sigilon Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04541628
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sigilon Therapeutics, Inc.